MedTrace Logo

Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder

NCT01075126 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-02-24

No results posted yet for this study

Summary

It is hypothesized that Depakote will be better tolerated then lithium in treating African Americans with bipolar disorder.

Conditions

Interventions

DRUG

Depakote

DRUG

Lithium

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Lawson, William B., M.D., PhD, DFAPA

    lead INDIV

Principal Investigators

  • William B. Lawson, MD, PhD · Professor and Chair, Howard University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2006-12-31
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075126 on ClinicalTrials.gov